RESUMEN
Cases of upper tracheal stenosis due to cervical schwannoma are fairly rare; therefore, no treatment has been determined. In this case, our patient had been treated for asthma for 4 years and was admitted to our hospital because of exacerbation. Computed tomography showed a tracheal stenosis lesion just below the vocal cords, and a biopsy revealed schwannoma. Conservative therapy was preferred rather than tumour resection by surgery. Follow-up for 5 years showed no changes on imaging. Conservative treatment is considered as an option if the extratracheal tumour does not grow.
RESUMEN
In previous studies, we identified 29 tumor-associated antigens (TAAs) and isolated 488 human monoclonal antibodies (mAbs) that specifically bind to one of the 29 TAAs. In the present study, we performed histochemical analysis of 36 freshly resected lung cancer tissues by using 60 mAbs against 27 TAAs. Comparison of the staining patterns of tumor cells, bronchial epithelial cells, and normal pulmonary alveolus cells and interalveolar septum allowed us to determine the type and location of cells that express target molecules, as well as the degree of expression. The patterns were classified into 7 categories. While multiple Abs were used against certain TAAs, the differences observed among them should be derived from differences in the binding activity and/or the epitope. Thus, such data indicate the versatility of respective clones as anti-cancer drugs. Although the information obtained was limited to the lung and bronchial tube, bronchial epithelial cells represent normal growing cells, and therefore, the data are informative. The results indicate that 9 of the 27 TAAs are suitable targets for therapeutic Abs. These 9 Ags include EGFR, HER2, TfR, and integrin α6ß4. Based on our findings, a pharmaceutical company has started to develop anti-cancer drugs by using Abs to TfR and integrin α6ß4. HGFR, PTP-LAR, CD147, CDCP1, and integrin αvß3 are also appropriate targets for therapeutic purposes.
Asunto(s)
Anticuerpos Monoclonales/uso terapéutico , Antígenos de Neoplasias/clasificación , Antineoplásicos/uso terapéutico , Neoplasias Pulmonares/tratamiento farmacológico , Terapia Molecular Dirigida/métodos , Anticuerpos Monoclonales/biosíntesis , Antígenos de Neoplasias/genética , Antígenos de Neoplasias/inmunología , Antineoplásicos/metabolismo , Bronquios/efectos de los fármacos , Bronquios/inmunología , Bronquios/patología , Bronquios/cirugía , Células Epiteliales/efectos de los fármacos , Células Epiteliales/inmunología , Células Epiteliales/patología , Epítopos/química , Epítopos/inmunología , Receptores ErbB/antagonistas & inhibidores , Receptores ErbB/genética , Receptores ErbB/inmunología , Expresión Génica , Humanos , Integrina alfa6beta4/antagonistas & inhibidores , Integrina alfa6beta4/genética , Integrina alfa6beta4/inmunología , Neoplasias Pulmonares/genética , Neoplasias Pulmonares/inmunología , Neoplasias Pulmonares/cirugía , Biblioteca de Péptidos , Receptor ErbB-2/antagonistas & inhibidores , Receptor ErbB-2/genética , Receptor ErbB-2/inmunología , Receptores de Transferrina/antagonistas & inhibidores , Receptores de Transferrina/genética , Receptores de Transferrina/inmunologíaRESUMEN
We report a case of single-incision bilateral partial lung resection using the subxiphoid approach. This approach requires a 3-cm incision in the abdomen, making it aesthetically favorable. In addition, it does not cause postoperative intercostal neuropathy, and postoperative pain is minimal because the intercostal space is bypassed. Moreover, this technique enables exposure to both lungs through a single incision and has potential for widespread use if maneuverability can be increased by improving the instruments used.
Asunto(s)
Neoplasias Colorrectales/patología , Neoplasias Pulmonares/secundario , Neoplasias Pulmonares/cirugía , Metastasectomía/métodos , Neumonectomía/métodos , Humanos , Masculino , Persona de Mediana Edad , Apófisis XifoidesRESUMEN
We report a surgical procedure in which a port and devices designed for single-incision endoscopic surgery are employed for thymectomy through an infrasternal approach. As this single-port thymectomy procedure can be performed through a single 3.5-cm incision in the abdominal region usually concealed under clothes, it is esthetically excellent and is among the least invasive thymectomy procedures because no sternal incision is applied and no intercostal nerve is injured. Investigation of the safety of this procedure and long-term therapeutic outcomes for myasthenia gravis and anterior mediastinal tumors is necessary.
Asunto(s)
Miastenia Gravis/cirugía , Esternotomía/instrumentación , Toracoscopios , Timectomía/métodos , Anciano de 80 o más Años , Femenino , Estudios de Seguimiento , HumanosRESUMEN
The search for effective antibodies (Ab) for curable cancer immunotherapy has been a quest of many research groups in order to find an effective target that exists on the cancer cell surface. So far there have been no conclusive answers to shed light on the search. This study therefore aimed to bridge the gap of cancer therapy. Screening against 49 kinds of cell lines belonging to 11 kinds of solids cancers was performed. Isolation and characterization for approximately 4200 monoclonal antibodies (mAb) was also performed thereafter. Of those mAb 488 clones that turned out to bind to 29 tumor-associated antigens (TAA) were subjected to immunohistochemical (IHC) analyses. Selection of target antigens (Ag) and a potential antibody for cancer therapy was conducted prior to clinical examinations. In order to find predictably effective targets for therapeutic Ab against solid cancers, expression of the Ag on the surface of cancer and normal cells was extensively examined by IHC analyses using fresh cancer specimens resected from patients. In this study, the tendencies of all staining patterns and distribution of the Ab are reported. While all of the TAA appeared to be involved in tumorigenesis, their expression was not restricted to some specific tumor types but rather randomly distributed among various cancers. Some kinds of Ab including anti-epidermal growth factor receptor (EGFR) and anti-human epidermal growth factor receptor 2 (HER2) indicated the frequency of expression in normal cells was generally low. We concluded that identification of 488 mAb and the accumulated results of IHC analyses in this study could be the key for further therapeutic Ab against cancers. The targets that showed cancer-specific expression are expected to be better for therapeutic Ab than the other Ab. Moreover, further investigation into the growth of cancer cell lines using full human IgG form of Ab shows available efficacy in specific cases.
Asunto(s)
Anticuerpos Monoclonales/uso terapéutico , Anticuerpos Antineoplásicos/uso terapéutico , Biblioteca de Péptidos , Citotoxicidad Celular Dependiente de Anticuerpos , Antígenos de Neoplasias/análisis , Antígenos de Neoplasias/inmunología , Proliferación Celular/efectos de los fármacos , Humanos , InmunohistoquímicaRESUMEN
We reported comprehensive screening for antigens (Ags) overexpressed on various carcinomas via isolation of human monoclonal antibodies (mAbs) that may be therapeutic in a previous paper (Proc. Natl. Acad. Sci. USA 105, 7287-7292, 2008). Twenty-one distinct Ags highly expressed on several carcinomas were identified and 356 mAbs with unique sequences turned out to bind to one of the 21 Ags. Among them CADM1/IGSF4 which had been originally referred to as tumor suppressor lung cancer 1 (TSLC1) was included. Therefore we examined the expression of CADM1 in lung cancers in this study. Eight different anti CADM1 mAbs were used for immunohistochemical analysis of 29 fresh lung cancer specimens. Staining patterns were categorized to six groups based on the extent of positive staining and the localization of stained portions. While overexpression of CADM1 was observed on the cell surface of adenocarcinomas at a high frequency, around 60%, positive stainings were rarely observed on that of other lung carcinomas including squamous cell carcinomas. Moreover, some clones among the eight mAbs gave different staining patterns from those by the other clones against the same fresh specimen, suggesting presence of variant forms of CADM1 differentiated by mAbs.
Asunto(s)
Adenocarcinoma/inmunología , Antígenos de Neoplasias/biosíntesis , Inmunoglobulinas/biosíntesis , Neoplasias Pulmonares/inmunología , Proteínas de la Membrana/biosíntesis , Proteínas Supresoras de Tumor/biosíntesis , Secuencia de Aminoácidos , Anticuerpos Monoclonales/inmunología , Antígenos de Neoplasias/inmunología , Molécula 1 de Adhesión Celular , Moléculas de Adhesión Celular , Epítopos/inmunología , Humanos , Inmunoglobulinas/inmunología , Proteínas de la Membrana/inmunología , Proteínas Supresoras de Tumor/inmunologíaRESUMEN
Although several murine mAbs that have been humanized became useful therapeutic agents against a few malignancies, therapeutic Abs are not yet available for the majority of the human cancers because of our lack of knowledge of which antigens (Ags) can become useful targets. In the present study we established a procedure for comprehensive identification of such Ags through the extensive isolation of human mAbs that may become therapeutic. Using the phage-display Ab library we isolated a large number of human mAbs that bind to the surface of tumor cells. They were individually screened by immunostaining, and clones that preferentially and strongly stained the malignant cells were chosen. The Ags recognized by those clones were isolated by immunoprecipitation and identified by MS. We isolated 2,114 mAbs with unique sequences and identified 21 distinct Ags highly expressed on several carcinomas. Of those 2,114 mAbs 356 bound specifically to one of the 21 Ags. After preparing complete IgG(1) Abs the in vitro assay for Ab-dependent cell-mediated cytotoxicity (ADCC) and the in vivo assay in cancer-bearing athymic mice were performed to examine antitumor activity. The mAbs converted to IgG(1) revealed effective ADCC as well as antitumor activity in vivo. Because half of the 21 Ags showed distinct tumor-specific expression pattern and the mAbs isolated showed various characteristics with strong affinity to the Ag, it is likely that some of the Ags detected will become useful targets for the corresponding carcinoma therapy and that several mAbs will become therapeutic agents.
Asunto(s)
Anticuerpos Monoclonales/química , Carcinoma/inmunología , Neoplasias/inmunología , Animales , Antígenos de Neoplasias/química , Antineoplásicos/farmacología , Carcinoma/diagnóstico , Línea Celular Tumoral , Receptores ErbB/metabolismo , Humanos , Inmunoglobulina G/metabolismo , Inmunoterapia/instrumentación , Inmunoterapia/métodos , Ratones , Ratones Desnudos , Modelos Biológicos , Neoplasias/diagnóstico , Biblioteca de PéptidosRESUMEN
In recent years, tumors producing granulocyte-colony-stimulating factor have been reported in an increasing number of patients, the majority of which have lung cancer. We experience a case of lung carcinoma producing granulocyte-colony-stimulating factor treated by resection and chemotherapy. He remains well 2 years and 10 months after surgery, with no recurrence of the carcinoma.
Asunto(s)
Carcinoma de Células Grandes/metabolismo , Factor Estimulante de Colonias de Granulocitos/biosíntesis , Neoplasias Pulmonares/metabolismo , Carcinoma de Células Grandes/sangre , Carcinoma de Células Grandes/patología , Carcinoma de Células Grandes/terapia , Humanos , Recuento de Leucocitos , Neoplasias Pulmonares/sangre , Neoplasias Pulmonares/patología , Neoplasias Pulmonares/terapia , Masculino , Persona de Mediana Edad , Tomografía Computarizada por Rayos XAsunto(s)
Secuestro Broncopulmonar/cirugía , Cirugía Torácica Asistida por Video , Niño , Humanos , MasculinoRESUMEN
PURPOSE: To determine if Noguchi's classification can be evaluated accurately by frozen-section diagnosis before limited surgery. METHODS: We performed frozen-section diagnosis in 31 of 343 patients who underwent excision of primary lung cancer at our hospital between 1993 and 2004. All 31 patients had pulmonary adenocarcinoma, with a tumor diameter of < or = 20 mm. There were 20 men and 11 women, ranging in age from 42 to 79 years (mean, 63.2 years). We assessed the rate of correct Noguchi's classification by categorizing all lesions into the following three groups on the basis of tumor diameter: < or = 10 mm, 11-15 mm, and 16-20 mm. RESULTS: The overall rate of correct frozen-section diagnosis during surgery was 67.7%; being 100%, 41.7%, and 70% in the < or = 10 mm, 11-15 mm, and 16-20 mm groups, respectively. CONCLUSION: Limited surgery for primary lung cancer can be performed when the tumor diameter is < or = 10 mm, by confirming it as either type A or B according to Noguchi's classification, using frozen-section diagnosis. Thus, examination of frozen sections might be an important diagnostic procedure before intentional limited surgery for lung cancer.
Asunto(s)
Adenocarcinoma/patología , Adenocarcinoma/cirugía , Secciones por Congelación , Neoplasias Pulmonares/patología , Neoplasias Pulmonares/cirugía , Adenocarcinoma/clasificación , Adulto , Anciano , Femenino , Humanos , Neoplasias Pulmonares/clasificación , Masculino , Persona de Mediana Edad , Neumonectomía/métodosRESUMEN
Thymic carcinoid in multiple endocrine neoplasia type 1 (MEN 1) is previously reported as a non-ACTH producing tumor. The present case is a 39-year-old man with mortal outcome from thymic carcinoid and Cushing's syndrome with high plasma ACTH. The symptom was first observed at age 29 and was relieved after extended thymectomy, with reduction of ACTH level. The tumor was positive for ACTH, Grimelius silver staining and Chromogranin A. The finding of primary hyperparathyroidism, pituitary adenoma, and a novel germline nonsense mutation (W423X) established the diagnosis of MEN 1. Cushing's syndrome due to ACTH producing thymic carcinoid should be also considered as one phenotype of the MEN 1 spectrum.
Asunto(s)
Síndrome de ACTH Ectópico/etiología , Tumor Carcinoide/complicaciones , Síndrome de Cushing/etiología , Neoplasia Endocrina Múltiple Tipo 1/diagnóstico , Neoplasias del Timo/complicaciones , Síndrome de ACTH Ectópico/sangre , Hormona Adrenocorticotrópica/sangre , Adulto , Antineoplásicos Hormonales/uso terapéutico , Protocolos de Quimioterapia Combinada Antineoplásica/administración & dosificación , Tumor Carcinoide/sangre , Tumor Carcinoide/patología , Tumor Carcinoide/terapia , Terapia Combinada , Síndrome de Cushing/sangre , Resultado Fatal , Mutación de Línea Germinal , Humanos , Masculino , Neoplasia Endocrina Múltiple Tipo 1/sangre , Neoplasia Endocrina Múltiple Tipo 1/genética , Neoplasia Endocrina Múltiple Tipo 1/terapia , Octreótido/uso terapéutico , Radioterapia Adyuvante , Timectomía , Neoplasias del Timo/sangre , Neoplasias del Timo/patología , Neoplasias del Timo/terapiaRESUMEN
Hepatic resection for colorectal metastases was performed for 188 patients. Overall survival rates after the first hepatectomy are 41.4% and 32.7% for 5 and 10 years, respectively. The survival rate of 116 cases with unilobar hepatic metastases (H1) is significantly higher than those of 48 cases with two to four bilobar metastases (H2) and 24 cases with more than four (H3), respectively. However, the differences between the survival rates from H1 with multiple metastases, H2, and H3 are not significant, even though the H3 group has no 10-year survivors. The 5-year survival rates after the second hepatectomy (30 patients) and the resection of the lung (26 patients) are 30.3% and 35.2%, respectively, in this series. In those patients, the 5-year survival rates from the first metastasectomy are 43.4% and 50.3%, respectively. There are 14 5-year survivors with multiple metastases and 8 of those patients underwent multiple surgeries. There are 13 patients with three or more repeat resections of the liver and/or lung. The 5-year survival rates of the patients from the first and third metastasectomy are 53.9% and 22.5%, respectively. Repeat operations for the liver and the lung contribute to the improving prognosis.
Asunto(s)
Neoplasias del Colon/patología , Hepatectomía , Neoplasias Hepáticas/secundario , Neoplasias del Recto/patología , Femenino , Humanos , Neoplasias Hepáticas/cirugía , Neoplasias Pulmonares/secundario , Neoplasias Pulmonares/cirugía , Metástasis Linfática/patología , Masculino , Persona de Mediana Edad , Neumonectomía , Pronóstico , Reoperación , Tasa de SupervivenciaRESUMEN
Myelolipoma is a rare tumor, and a mediastinal location is extremely unusual. The main pathologic feature is the coexistence of mature adipose tissue and bone marrow cells; the presence of megakaryocytes is essential for diagnosis. The successful removal of a mediastinal myelolipoma in a 59-year-old man is described.